This is an open-label, multicenter, Phase 1 study of LT-010391, a selective and orally bioavailable KRAS G12D degrader in participants with KRAS G12D mutant advanced solid tumors to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity. The study consists of two parts: Part A- dose escalation and Part B- dose expansion.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with histologically or cytologically confirmed advanced solid tumors harboring a KRAS G12D mutation;
Failed standard therapy, intolerant to standard therapy, or no standard therapy is available;
ECOG Performance Status of 0 or 1;
Adequate organ function
You may not be if
History of ≥2 primary malignancies within 5 years prior to signing informed consent, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or other malignancies considered cured;